I partner with my clients to protect and advance innovations that help improve people’s lives

Experience

Goldfinch Bio Announces Strategic Collaboration with Gilead

October 29, 2020

Goldfinch Bio on its strategic collaboration with Gilead Sciences to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.

Under the terms of the agreement, Goldfinch will receive $55 million in upfront payments, which includes a $5 million equity investment, and an additional $54 million to support the development of the KGA platform for DKD. Goldfinch is also eligible to receive up to $1.95 billion in potential payments for the first five collaboration programs based on the successful achievement of research, development, regulatory and commercial milestones, and tiered royalties on sales of potential products originating from the collaboration. Additionally, Goldfinch retains the option to equally share in US profits for certain optioned products in certain pre-defined kidney indications.


Related contacts

Lila Hope
Partner, Palo Alto
Chen Chen
Associate, Palo Alto
Chen Chen
Partner, Boston

Related Practices & Industries

Zealand Pharma – $89 Million IPO

August 8, 2017

Cooley advised the underwriters on Zealand Pharma A/S’s $89 million initial public offering of 5,031,250 American Depositary Shares in the United States, which includes the full exercise of the underwriters’ option to purchase additional shares.

Read more

Related contacts

Josh Kaufman
Partner, New York
Div Gupta
Partner, New York
Charlie Kim
Partner, San Diego
Dayne Brown
Associate, New York
Natasha Leskovsek
Of Counsel, Washington DC
Heidi A. Erlacher
Partner, Boston
Chen Chen
Partner, Boston
Stephanie Gentile
Partner, New York
Francis Wheeler
Partner, Colorado

Related Practices & Industries

Memberships & affiliations

American Bar Association

Boston Patent Law Association